NYSE: $MRK
RAHWAY, N.J.–(BUSINESS WIRE) October 26, 2026 — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab…
Source: Read More